Tisdale J E, Sun H, Zhao H, Fan C D, Colucci R D, Kluger J, Chow M S
Hartford Hospital, University of Connecticut, USA.
J Cardiovasc Pharmacol. 1996 Mar;27(3):376-82. doi: 10.1097/00005344-199603000-00010.
The primary objective of this study was to determine the effect of esmolol, administered alone and in combination with lidocaine, on ventricular fibrillation threshold (VFT) in pigs. A secondary objective was to determine the relationship between blood esmolol concentrations and VFT. We determined VFT using a train of electrical stimuli delivered to the right ventricle after eight paced beats at a basic cycle length of 285 ms. Current was increased in 2-mA increments until VF occurred. VFT determinations were performed during administration of esmolol 1,000 mu g/kg/min, during a continuous infusion of lidocaine, and during infusion of esmolol and lidocaine in combination. Mean increases in VFT from baseline during infusion of esmolol and lidocaine alone were 32.3 +/- 12.9 and 8.5 +/- 7.2 mA, respectively (p < 0.05, each drug compared with baseline; p < 0.05, esmolol vs. lidocaine). Mean increase in VFT from baseline during infusion of the combination was 52.0 +/- 22.0 mA (p < 0.05 as compared with baseline and with esmolol or lidocaine alone). The relationship between blood esmolol concentrations and VFT was described by a counterclockwise hysteresis curve, suggesting delay in equilibration of esmolol between blood and site of effect. The antifibrillatory efficacy of esmolol is significantly greater than that of lidocaine in this model. Administration of the two agents in combination resulted in significantly greater antifibrillatory efficacy than that associated with either drug administered alone.
本研究的主要目的是确定艾司洛尔单独使用以及与利多卡因联合使用时,对猪心室颤动阈值(VFT)的影响。次要目的是确定血液中艾司洛尔浓度与VFT之间的关系。我们在以285毫秒的基本周期长度进行8次起搏搏动后,通过向右心室施加一串电刺激来测定VFT。电流以2毫安的增量增加,直至发生室颤。在输注1000微克/千克/分钟的艾司洛尔期间、持续输注利多卡因期间以及输注艾司洛尔和利多卡因的联合制剂期间进行VFT测定。单独输注艾司洛尔和利多卡因期间,VFT相对于基线的平均增加分别为32.3±12.9毫安和8.5±7.2毫安(每种药物与基线相比,p<0.05;艾司洛尔与利多卡因相比,p<0.05)。联合制剂输注期间,VFT相对于基线的平均增加为52.0±22.0毫安(与基线以及单独使用艾司洛尔或利多卡因相比,p<0.05)。血液中艾司洛尔浓度与VFT之间的关系由一条逆时针滞后曲线描述,这表明艾司洛尔在血液与作用部位之间达到平衡存在延迟。在该模型中,艾司洛尔的抗纤颤疗效显著大于利多卡因。两种药物联合使用的抗纤颤疗效显著大于单独使用任何一种药物时的疗效。